Gene Expression Profiling Predicts Clinical Outcome of Prostate Cancer

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Apr 7

PMID 15067324

Citations 218

Authors

Gennadi V Glinsky

Anna B Glinskii

Andrew J Stephenson

Robert M Hoffman

William L Gerald

Affiliations

Soon will be listed here.

Abstract

One of the major problems in management of prostate cancer is the lack of reliable genetic markers predicting the clinical course of the disease. We analyzed expression profiles of 12,625 transcripts in prostate tumors from patients with distinct clinical outcomes after therapy as well as metastatic human prostate cancer xenografts in nude mice. We identified small clusters of genes discriminating recurrent versus nonrecurrent disease with 90% and 75% accuracy in two independent cohorts of patients. We examined one group of samples (21 tumors) to discover the recurrence predictor genes and then validated the predictive power of these genes in a different set (79 tumors). Kaplan-Meier analysis demonstrated that recurrence predictor signatures are highly informative (P < 0.0001) in stratification of patients into subgroups with distinct relapse-free survival after therapy. A gene expression-based recurrence predictor algorithm was informative in predicting the outcome in patients with early-stage disease, with either high or low preoperative prostate-specific antigen levels and provided additional value to the outcome prediction based on Gleason sum or multiparameter nomogram. Overall, 88% of patients with recurrence of prostate cancer within 1 year after therapy were correctly classified into the poor-prognosis group. The identified algorithm provides additional predictive value over conventional markers of outcome and appears suitable for stratification of prostate cancer patients at the time of diagnosis into subgroups with distinct survival probability after therapy.

Citing Articles

Downregulated Regucalcin Expression Induces a Cancer-like Phenotype in Non-Neoplastic Prostate Cells and Augments the Aggressiveness of Prostate Cancer Cells: Interplay with the G Protein-Coupled Oestrogen Receptor?.

Fonseca L, Carreira R, Feijo M, Cavaco J, Cardoso H, Vaz C Cancers (Basel). 2024; 16(23).

PMID: 39682121 PMC: 11640704. DOI: 10.3390/cancers16233932.

The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response.

Guo W, Zong S, Liu T, Chao Y, Wang K Front Pharmacol. 2024; 15:1476025.

PMID: 39494345 PMC: 11530994. DOI: 10.3389/fphar.2024.1476025.

Comparison of RNA-Seq and microarray in the prediction of protein expression and survival prediction.

Kim W, Choi B, Noh J, Lee Y, Kim T, Lee J Front Genet. 2024; 15:1342021.

PMID: 38463169 PMC: 10920353. DOI: 10.3389/fgene.2024.1342021.

Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial.

Bitting R, Wu Y, Somarelli J, Proudfoot J, Liu Y, Davicioni E JCO Precis Oncol. 2023; 7:e2300214.

PMID: 37595184 PMC: 10581641. DOI: 10.1200/PO.23.00214.

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

Passier M, van Genderen M, Zaalberg A, Kneppers J, Bekers E, Bergman A Cancer Res Commun. 2023; 3(8):1473-1485.

PMID: 37554550 PMC: 10405859. DOI: 10.1158/2767-9764.CRC-23-0097.

References

Luo J, Duggan D, Chen Y, Sauvageot J, Ewing C, Bittner M . Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 2001; 61(12):4683-8. View

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View

Latulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V . Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002; 62(15):4499-506. View

Holmberg L, Bill-Axelson A, Helgesen F, Salo J, Folmerz P, Haggman M . A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002; 347(11):781-9. DOI: 10.1056/NEJMoa012794. View

Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

Ramaswamy S, Ross K, Lander E, Golub T . A molecular signature of metastasis in primary solid tumors. Nat Genet. 2002; 33(1):49-54. DOI: 10.1038/ng1060. View

DeMarzo A, Nelson W, Isaacs W, Epstein J . Pathological and molecular aspects of prostate cancer. Lancet. 2003; 361(9361):955-64. DOI: 10.1016/S0140-6736(03)12779-1. View

Chen C, Hyytinen E, Sun X, Helin H, Koivisto P, Frierson Jr H . Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol. 2003; 162(4):1349-54. PMC: 1851229. DOI: 10.1016/S0002-9440(10)63930-2. View

10.

Reya T, Duncan A, Ailles L, Domen J, Scherer D, Willert K . A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003; 423(6938):409-14. DOI: 10.1038/nature01593. View

11.

Willert K, Brown J, Danenberg E, Duncan A, Weissman I, Reya T . Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003; 423(6938):448-52. DOI: 10.1038/nature01611. View

12.

Glinsky G, Krones-Herzig A, Glinskii A . Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. Neoplasia. 2003; 5(3):218-28. PMC: 1502409. DOI: 10.1016/S1476-5586(03)80054-4. View

13.

Henshall S, Afar D, Hiller J, Horvath L, Quinn D, Rasiah K . Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003; 63(14):4196-203. View

14.

Glinsky G, Krones-Herzig A, Glinskii A, Gebauer G . Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Mol Carcinog. 2003; 37(4):209-21. DOI: 10.1002/mc.10139. View

15.

Glinsky G, Ivanova Y, Glinskii A . Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification. Cancer Lett. 2003; 201(1):67-77. DOI: 10.1016/s0304-3835(03)00419-1. View

16.

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

17.

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

18.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S . Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999; 36(1):21-30. DOI: 10.1159/000019922. View

19.

DAmico A, Whittington R, Malkowicz S, Fondurulia J, Chen M, Kaplan I . Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999; 17(1):168-72. DOI: 10.1200/JCO.1999.17.1.168. View

20.

Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A . Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002; 62(15):4427-33. View